The effect of clindamycin on survival of mice during acute infection with the RH and C56 strains of Toxoplasma and the ability of this drug to prevent congenital transmission during the acute stage of the infection in the mother and to eradicate the parasite from tissues of mice chronically infected with the C56 strain were evaluated. The drug effectively prevented death due to the acute infecton and, in the experimental model employed, eradicated the organism at least from the liver, spleen, and brain of approximately 30 to 50% of the acutely infected animals which survived. Clindamycin also effectively prevented congenital transmission during the acute infection in the mother. During short-term treatment (7 days), persistent parasitemia in the chronic infection was effectively diminished or eradicated. More prolonged treatment resulted in a significant clearing of the organisms from the spleens and livers,\but not from the brains, of chronically infected mice.
The present drug regimen used in the treatment of toxoplasmosis is the combination of pyrimethamine with sulfadiazine (or triple sulfanomides). The potential toxicity to the bone marrow associated with pyrimethamine treatment of toxoplasmosis in both immunologically normal and immunologically deficient individuals (12) has caused investigators to search for alternative modes of therapy. In addition, since pyrimethamine is an antimetabolite, it must be considered potentially teratogenic (11) , and we, as well as another (14) , have advised against use of this drug early in pregnancy. In the United States, no other drug or drug combination has been considered acceptable for treatment of toxoplasmosis. In Europe, spiramycin (7) has been employed extensively, but there are few control studies (2) in animals or in man to allow one to determine objectively the efficacy of this antibiotic.
What is needed is an effective, nontoxic drug or drug combination that can be employed safely in normal infants, in older children and adults, and in patients on immunosuppressive therapy during pregnancy. We have been evaluating certain of the newer antimicrobial agents as they have appeared-most recently, rifampin (19) and trimethoprim (4) -both of which have proven disappointing in experiments carried out in vivo.
The recent demonstration of the efficacy of clindamycin in the treatment of-acute toxoplasmosis in a mouse model by McMaster and his colleagues (10) was the impetus for the present study. Since Toxoplasma can be transmitted congenitally (13) and persists in the tissues of a large percentage of the normal population of the United States and in the rest of the world (5), we were interested in determining the effect of this antibiotic in preventing congenital transmission and its effect on the persistence of the parasite during the chronic (latent) infection.
ARAUJO AND REMINGTON
Toxoplasma gondii was accomplished as described previously (20) . For mission of Toxoplasma from an acutely infected mother to her offspring in utero, pregnant mice were infected i.p. with 105 trophozoites of the RH strain of Toxoplasma and given clindamycin (6 mg/4 g of food) in their diet immediately thereafter. Controls were infected pregnant mice which received no clindamycin in their diet. Subinoculation results revealed that of the 11 infected controls, 9 gave birth to infected offspring or were delivered of infected offspring by caesarian section. They had a total of 44 infected offspring. Of the 7 infected mice treated with clindamycin, none gave birth to or were delivered of infected offspring (the size of the litters varied from 4 to 14 offspring). The number of days of clindamycin treatment prior to delivery in both infected and treated and untreated groups was approximately 8 to 14 days. There was no appreciable difference in duration of infection between the treated group and the untreated control group. The number and health of the offspring delivered by uninfected pregnant mice which had been treated with clindamycin alone was similar to that observed in untreated, uninfected normal pregnant mice in our laboratory.
Effect of clindamycin on persistent parasitemia in chronically infected mice. Mice chronically infected with the C56 strain 5 months previously were treated with a diet containing 6 mg of clindamycin per 4 g of food. On days 7, 14 , and 21 of treatment, the clindamycin was discontinued in the diet; 48 h later mice were bled, and the total volume of blood (approximately 1.5 bined results are shown in Table 6 . Whereas parasitemia was demonstrable in 50% of untreated mice, none of the treated mice had demonstrable parasitemia after 7 days of treatment. Similar results were found after 14 and 21 days of therapy. tion. The results revealed that a significant decrease in the number of organisms occurred only in the peripheral tissues. It is not surprising, however, that clindamycin did not effectively eradicate organisms from the brain, since lincomycin penetrates into the nervous system and cerebrospinal fluid poorly (9) . Of interest is the fact that sulfadiazine also effectively reduced the number of parasites in peripheral tissues of mice with the latent infection. Its lack of effect on the infection in the brain may have been due to too low a dose, since this drug does cross the cerebrospinal fluid and bloodbrain barrier (21) . Our results suggest that each of these antimicrobial agents is able to effectively enter the tissue cyst and act on the encysted parasites. Whether this is the mechanism whereby the drugs acted, however, remains to be clarified.
The doses of clindamycin most effective in the present study appear higher than those ordinarily used in man (approximately 250 mg per kg per 24 h in the mice compared with approximately 15 to 30 mg per kg per 24 h used in man) when calculated on a milligram per kilogram basis. However, when the doses are equated on a comparable surface area basis (a much more reliable measure), the dose for the mice was 750 mg/m2, which is comparable to the dose of 550 to 1,100 mg/M2 usually used in man. Whether clindamycin is metabolized in mice at the same rate as in man is unknown.
The results reported here suggest that clindamycin may be of value in treatment of latent infection with Toxoplasma and, in agreement with the results of McMaster et al. (10) , in the treatment of acute toxoplasmosis. Before any recommendations can be made, however, results of carefully controlled studies in man must be forthcoming.
